This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Top Research Reports for Netflix, Medtronic & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Medtronic (MDT), and AstraZeneca (AZN).
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
LabCorp (LH) Expands Testing Portfolio With the Launch of CDx
by Zacks Equity Research
LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
Top Analyst Reports for Alphabet, Visa & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and Eli Lilly (LLY).
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status
by Zacks Equity Research
Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
by Zacks Equity Research
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab
by Zacks Equity Research
FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study
by Zacks Equity Research
AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.
QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS
by Zacks Equity Research
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment
by Zacks Equity Research
Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.